0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED...
Transcript of 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED...
![Page 1: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/1.jpg)
![Page 2: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/2.jpg)
DISCLOSURESBAXTER SAB MEMBER
BDSLICENSINGAGREEMENT
CYTORI SAB MEMBER
THEROX INVESTOR
![Page 3: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/3.jpg)
LISTOFPHASEIII POSITIVETRIALS
![Page 4: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/4.jpg)
TRIALS2015REFRACTORY ANGINA
BAXTER CD34 PHASE III, TERMINATEDCYTORI PHASE II, TERMINATED
REFRACTORY CHFCUPID NEGATIVEMESOBLAST, TEVA ONGOINGSDF1, NEGATIVEAASTROM PHASE II CONCLUDEDCYTORI, TERMINATED
POST MIALLSTAR CARDIOSPHERE PHASE II COMPLETEDANGIOBLAST (OUS AMICI PHASE II, REVASCOR)AMORCYTE PHASE II, CONCLUDED
![Page 5: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/5.jpg)
ROGUECLINICS
![Page 6: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/6.jpg)
![Page 7: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/7.jpg)
THE HITMAN͟
![Page 8: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/8.jpg)
YOU CAN’TMAKETHISUPGionisSentenced to 5 Yearsfor WayneAttack : Court: The judgesays theex-husband ofJohn Wayne'sdaughter hasa 'dangerouscombination . . . of no remorseand a need tocontrol.'July 07, 1992|MARK I. PINSKY | TIMESSTAFF WRITERSANTA ANA — Theex-husband of John Wayne'sdaughter wassentenced Monday to fiveyears in prison for masterminding an attack that a judgesaid went "way beyond what anormal husband would do in adivorcesituation."Dr. ThomasGionis, 38, appeared calm ashewassentenced for soliciting thebeating inwhich two hired thugsbound AissaWayne, 36, and slammed her face into agarage f looron Oct. 3, 1988. Gionisand Waynewere locked in abitter custody battleat thetime.Theattackersalso bound Wayne's then-boyfriend, Roger Luby, pistol-whipping him andslashing hisAchillestendon during theattack at Luby's Newport Beach estate.In addition to theprison sentence, Superior Court JudgeTheodoreE. Millard fined thePomomaphysician $10,000 and ordered him to serve threeyears' probation aftercompleting hisprison sentence. The judgeestimated that, with work credits, Gioniscould be free in as litt leas2 1/2 years.
![Page 9: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/9.jpg)
![Page 10: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/10.jpg)
CELLULARREGENERATIONTISSUE REPAIR
TISSUE GROWTH
MESENCHYMAL CELL LINES
![Page 11: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/11.jpg)
PATIENTPOPULATIONSREFRACTORY ANGINA
REFRACTORY CHF
POST MI REMODELING
![Page 12: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/12.jpg)
CELLTHERAPYOPTIONSAUTOLOGOUSCELLS
UNFRACTIONATED BONE MARROW
ADIPOSE DERIVED STEM CELLS
CARDIOSPHERES
TMR + PRP
SKELETAL MYOBLAST
IPS
ALLOGENIC CELLS
ANGIOBLAST (MESENCHYMAL)
CARDIOSPHERES
SDF
![Page 13: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/13.jpg)
ISSUESWHYHASITTAKEN SOLONG?
EARLYTRIALSNEGATIVE
POORSTUDYDESIGN
POORPATIENT SELECTION
END POINT CHAOS
DOSING CHAOS
WRONGAGENT
DELIVERYCATHETER/TECHNIQUE ISSUES
FINANCIAL FAILURE
BAD LUCK
![Page 14: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/14.jpg)
QUESTIONS1998HOW BEST DELIVER
DOSE
WHERE DO THEY GO
DO THEY GRAFT
DO THEY REPLICATE
DO THEY SURVIVE (LOW OXYGEN)
DO THEY REALLY DzWORKdz
![Page 15: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/15.jpg)
DELIVERYINTRACORONARY
INTRA MYOCARDIAL
EPICARDIAL
INTRAVENOUS
CORONARY SINUS
PERICARDIAL
![Page 16: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/16.jpg)
ENDPOINTCHAOSANGINA
SUBJECTIVECCS
NTG USE
SELF REPORTING (IVRS)
SAQ
OBJECTIVEETT TIME *
TIME TO ST CHANGE
TIME TO ANGINA
SPECT (SSS)
MORTALITY
CHFSUBJECTIVE
NYHA
MINN HF
OBJECTIVEV02 MAX
EF
PV LOOPS
REPEATHOSPITALIZATION
MORTALITY
DEFIB EVENTS
![Page 17: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/17.jpg)
NEGATIVETRIALSVIVA TRIAL: VEGF I PROTEIN
FIRST TRIAL: FGF PROTEIN
GENASISTRIAL: VEGF II GENE
AGENT TRIAL: FGF GENE/VECTOR
DzPLACEBO WORKSPRETTY GOOD!dz
![Page 18: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/18.jpg)
SCRIPPSTRIALS, COMPLETEDBAXTER PHASE II
AMORCYTE PHASE II
AASTROM PHASE II
CYTORI PHASE II
![Page 19: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/19.jpg)
![Page 20: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/20.jpg)
![Page 21: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/21.jpg)
![Page 22: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/22.jpg)
![Page 23: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/23.jpg)
![Page 24: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/24.jpg)
![Page 25: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/25.jpg)
![Page 26: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/26.jpg)
![Page 27: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/27.jpg)
![Page 28: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/28.jpg)
TWOYEARFOLLOW UP
![Page 29: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/29.jpg)
![Page 30: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/30.jpg)
![Page 31: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/31.jpg)
ANGINA RELIEF
![Page 32: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/32.jpg)
ETTRESULTS
![Page 33: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/33.jpg)
ACT34 MACE
![Page 34: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/34.jpg)
CADUCEUSTRIALCARDIOSPHERES
25 PATIENTSPHASE I
RANDOMIZED DOUBLE BLIND 2:1
POST STEMI 1.5-3 MONTHSPOST
BIOPSY DERIVED CDC VSSOC
PRIMARY ENDPOINT
6 MONTH MACE
SECONDARY ENDPOINT
MRI SCAR, WMA, VOLUMES
![Page 35: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/35.jpg)
CADUCEUSMRI RESULTS
![Page 36: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/36.jpg)
CADUCEUSMRI RESULTS
![Page 37: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/37.jpg)
CARDIOSPHERES
PHASE II
30 PATIENTS
POST ANTERIOR/ INFERIOR STEMI PCI
EF < 55%
UP TO 1YEAR POST STEMI
ALLOGENIC CELLS!
PRIMARY ENDPOINT
INFARCT SIZE BY MRI
![Page 38: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/38.jpg)
• Adipocytes
• Adult stem cells
• Endothelial cells
• Vasc. smooth muscle cells
• Tissue resident macrophages
• Perivascular cells
• …… ..
p g
Adipose Derived Regenerat iveCel ls• Adipocytes
• Adult stem cells
• Endothelial cells
• Vasc. smooth musclecells
• Tissue resident macrophages
• Perivascular cells
• …… ..
Adipose Tissue
Liposuction
Processing
![Page 39: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/39.jpg)
Adipose Tissue
Was hing media
Liquid fa t
Collagen/Adipocytes /Debris
Ce ll pe lle t/e rythroc ytes
Enzyme Digestion +Centrifugation
Right picture from TulaneUniversity
ADRCs
![Page 40: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/40.jpg)
![Page 41: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/41.jpg)
g y
Cell Type Frequency
Endothelial cell 7%
Smooth musclecell 9%
Blood cell 22%
Tissue Macrophage 23%
CD34+/CD31-/CD45- 38%
Stem Cells (CFU-F) 1-5%
![Page 42: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/42.jpg)
CYTORIATHENATRIAL
150 PT PHASE II
CHRONIC ICM/CHF/ANGINA
EF< 45%
RANDOMIZED DOUBLE BLIND 2:1
LIPOSUCTION ADRC VSPLACEBO
PRIMARY ENDPOINT
MVO2 AT 6 MONTHS
SECONDARY ENDPOINTS
MRI/SPECT/ANGINA RELIEF
ETT
![Page 43: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/43.jpg)
ATHENAPROTOCOLLIPOSUCTION INPATIENT
CELLSPROCESSED IN 1HOUR
NOGA MAP/ INJECTION 2-4 HOURS
D/C IN 24 HOURS
TERMINATED FOR 3 STROKES
![Page 44: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/44.jpg)
AASTROM TRIAL15O PATIENTSPHASE II
CHRONIC ISCHEMIC CHFBUT YOU DON’T HAVE TO BE ISCHEMIC!
EF < 35%
RANDOMIZED 1:1
ABM (IXMYELOCELL) VSPLACEBO
PRIMARY ENDPOINT
HOSPITAL ADMISSIONS OVER 12 MONTHS
SECONDARY ENDPOINTS
MVO2 MAX
![Page 45: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/45.jpg)
TEVATRIALRANDOMIZED DOUBLE BLIND
1700 PATIENTS52 SITES
ISCHEMIC AND NON ISCHEMIC
<45% EF
ALLOGENIC CELLS
NOGA DELIVERY
![Page 46: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/46.jpg)
Greenberg B. et al. Presented at ESC, London. Sept 1, 2015
![Page 47: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/47.jpg)
CUPID
![Page 48: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/48.jpg)
(Time to recurrent HF-related hospitalizationsand ambulatoryworseningHF)
Greenberg B. et al. Presented at ESC, London. Sept 1, 2015
• 232 total recurrentevents: 128 in placebogroup, 104 inAAV1/SERCA2a
• AAV1/SERCA2a fai ledto improve the rate ofrecurrent events (HR0.93p = 0.81)
• No benefi t insecondary orexploratory events
![Page 49: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/49.jpg)
y
![Page 50: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/50.jpg)
![Page 51: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/51.jpg)
![Page 52: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/52.jpg)
Sanz-RuizR. Eur Heart J2015. doi:10.1093/eurheartj/ ehv258
![Page 53: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/53.jpg)
p
Penn M. et al. Circ Res2013:112,816
Primary safety (MACE) endpoint wasmet
![Page 54: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/54.jpg)
Chung M. et al. Eur Heart 2015: doi:10.1093/eurheartj/ehv254
Characteristic Placebo 15 mg 30 mg
Demographics Patients (n) 31 32 30
Sex (%male) 90 88 90
NYHAClassIII (%) 69 61.3 70
Yearssince Last MI 13 + 11 10 + 7 10 + 9
Comorbidities Diabetic (%) 48.3 35.5 46.7
Age 67 +9 64 +11 64 +7
BMI 30 +5 29 +4 32 +7
LV Structure LVESV(ml) 158 +64 161 +63 183 +71
LVEDV(ml) 219 +68 228 +75 222 +76
LVEF(%) 30 +7 28 +8 26 +8
Clinical Status NTproBNP(pg/ml) 1259 +1373 1144 +1005 952 +802
6MWD(meters) 284 +98 295 +96 308 +73
MLWHFQ 56 +17 49 +18 47 +22
Baseline Therapy ACE-I/b-blocker/MRA(%) 84/94/48 78/91/62 80/93/63
Bi-V pacemaker (%) 54.8 53.1 43.3
![Page 55: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/55.jpg)
Chung M. et al. Eur Heart 2015: doi:10.1093/eurheartj/ehv254
• Primary endpointwas not met
• Safety endpointmet
• Placebo effect seen
• No signi f icantdi fference in LVEF,LVESV orNTproBNP witht reatmentcompared toplacebo
![Page 56: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/56.jpg)
Chung M. et al. Eur Heart 2015: doi:10.1093/eurheartj/ehv254
![Page 57: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/57.jpg)
Why did pSDF 1 fail in STOPHF?
![Page 58: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/58.jpg)
Timothy D. Henry, Carl J. Pepine, Charles R. Lambert, Jay H. Traverse,Richard Schatz, Marco Costa, Thomas J. Povsic, R. David Anderson,
Steven Kesten, JamesT. Willerson, Emerson C. Perin
![Page 59: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/59.jpg)
PRECISETRIALStudy Design
Double-blind, randomized, parallel group, placebo-controlledin 27 (21ADRC, 6 placebo) ischemic cardiomyopathy patientsin Europe
Procedure
EMM (NOGASTAR®Diagnostic Def lectableTip Catheter)
≤ 15 IM injections [ADRCs(n=21, median dose = 42 x 106 cells]
Resul ts
Suggested improvement in symptoms, MVO2 and areductionin reversible ischemia
Perin et al Adipose-derived regenerativecells in patientswith ischemiccardiomyopathy: ThePRECISETrial. Am Heart J2014; doi:10.1016/ j.ahj.2014.03.022.
![Page 60: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/60.jpg)
Return cells to thesame patient
Collect donortissue
1½hours
Separate andprocessADRCs
(Celution®)
![Page 61: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/61.jpg)
ATHENA: Study Design
61
![Page 62: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/62.jpg)
0
10
20
30
40
50
60
baseline 3 Month 6 Month 12 Month
ADRC
Placebo
p=0.154p=0.038
p=0.54
p=0.25
16 14 15 13 14 1314 16
![Page 63: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/63.jpg)
Number
(%)
Month 6 Month 12
ADRC Placebo ADRC Placebo
Improved 8 (62) 3 (27) 8 (67) 3 (27)
Same 4 (31) 8 (73) 4 (33) 8 (73)
Worsened 1 (8) 0 (0) 0 (0) 0 (0)
y p g
Number
(%)
Month 6 Month 12
ADRC Placebo ADRC Placebo
Improved 7 (47) 4 (31) 8 (57) 2 (15)
Same 6 (40) 6 (46) 4 (29) 8 (62)
Worsened 2 (13) 3 (23) 2 (14) 3 (23)
NYHA CCS
![Page 64: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/64.jpg)
6 months
*p<0.05
12 months
Changes from baseline in the ADRC (n=15) and placebo (n=13) groups
-15
-10
-5
0
5
10
15
20
25
30
35
PF RP BP GH V SF RE MH PC MC
*
*
**
-15
-10
-5
0
5
10
15
20
25
30
35
PF RP BP GH V SF RE MH PC MC
*
*
*
![Page 65: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/65.jpg)
mVO2 and LVEF
65
-20
-10
0
10
20
30
40
50
ADRC Placebo
mV
O2
(mL
/min
)
0
1
2
3
4
5
ADRC PlaceboLV
EF
(%)
mVO2 LVEF
Change from baseline to 6 months
p=0.495p=0.433
![Page 66: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/66.jpg)
Baseline (B) and 6 months (6) [ADRC n=15, Placebo n=12]
0
10
20
30
40
50
60
70
80
90
100
Fixed Reversible Stress
ADRC-B
ADRC-6
Placebo-B
Placebo-6
%LV
Type of Defect
p=0.44
p=0.40
p=0.07
![Page 67: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/67.jpg)
Safety Total (n=31) ADRC (n=17) Placebo (n=14) p-value
SeriousAdverse Events 18 (58.1%) 9 (52.9%) 9 (64.3%) 0.66
MACE 9 (29.0%) 6 (35.3%) 3 (21.4%) 0.46
Cardiac Death* 2 (6.5%) 2 (11.8%) 0 (0%) 0.49
MI 1 (3.2%) 1 (5.9%) 0 (0%) 1.0
Stroke/TIA 3 (9.7%) 2 (11.7%) 1 (7.1%) 1.0
Heart Failure
Hospital.5 (16.1%) 2 (11.7%) 3 (21.4%) 0.47
*decompensation of heart failure – day 291, myocardial ischemia – day 2 post-procedure
![Page 68: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/68.jpg)
ConclusionsSmall volume fat harvest, followed by automated localprocessing, and intramyocardial delivery of autologousADRCs is feasible
Symptom-based outcomes indicated beneficial trends:MLHFQ, SF-36, NYHA and CCS, HF Hosp, MVO2
No beneficial effect on LVEF
Observed cerebrovascular effects indicate need for patientselection and peri-procedure diligence
Although thesample issize is limited, the findingssupport feasibility and scalability for useof ADRCs fortreatment of ischemic heart disease
![Page 69: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/69.jpg)
Timothy D. Henry, ThomasJ. Povsic, Jay Traverse, F David Fortuin, Gary L Schaer,Dean J. Kereiakes, Richard A. Schatz, AndreasM. Zeiher, Christopher J. White,
Duncan J. Stewart, E. Marc Jolicoeur, Theodore Bass, David A. Henderson, PatriciaDignacco, Xianqiong Gu, Hussein R. Al-Khalidi, Candice Junge, Adel Nada, Andrea
Hunt, DouglasW. Losordo, on behalf of the RENEW Investigators
![Page 70: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/70.jpg)
ACT34 Study Design
70
Subjec t popula tion
(n=167)
• 21-80 yrs
• CCS clas s III or IV Angina
• Attempted “bes t”medical
therapy
• Non-candidate for
Surgica l/Perc . revas c .
• Is chemia on SPECT
• 3-10 min. mod. Bruce
protocol with angina or
anginal equiva lent a t bas e line
1 x 10^5 CD34+ cells /kg(n = 55)
5 x 10^5 CD34+ cells /kg(n = 56)
Endomyocardia l Mapping and Injec tion with NOGAIs olex s e lec ted CD34+ cells / P lacebo Rx
Cell Mobiliza tion (GCSF 5mcg/kg/d x 5d)Apheres is on Day 5
Follow-up Safe ty and Efficacy As s es s ments :1 - 7 days , and 1, 3, 6, and 12 months ; ETT at 3, 6, 12 months
MRI at 6 months , SPECT at 6 & 12 months
Screening and Bas eline Vis its
P lacebo(n = 56)
Randomization
![Page 71: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/71.jpg)
![Page 72: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/72.jpg)
y yEndpoints
Primary Efficacy Endpoint
Change in tota l exercise dura tion us ing a s tandardized
Modified Bruce Protocol ETT at 12 months
Secondary Efficacy Endpoints
Change in angina frequency at 12 months
Change in exercise dura tion and angina frequency a t 6
months
Explora tory Endpoints
Incidence of MACE* and SAEs in a ll subjects
72
* MACE: all death, non-fatal MI, CVA, Cardiac rehosp
![Page 73: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/73.jpg)
Statistical PlanSample Size
400 completed subjects
90% power to detect 60 seconddifference in mean change frombaseline in total exercise time
Sta tis tica l Approach
Closed form tes ting procedure onprimary and secondary efficacyendpoints
Allows for potentia l inclus ion ofsecondary efficacy endpoints inproduct label
![Page 74: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/74.jpg)
74
![Page 75: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/75.jpg)
CD34+
n=57
Consented n=297
Randomized n=112
ACn=27
SOCn=28
ITT Population
CD34+ n=54AC n=30
3patients with inadequatestudy product substituted with placebo
2 ptn pt
AC n=28
Not injectedn=6
CD34+ n=50AstreatedPopulation
![Page 76: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/76.jpg)
y p
D Mixed Model Range P-value
3-months 42.1 -20.6, 104.8 0.19
6-months 34.7 -37.7, 107.0 0.34
12-months 20.4 -68.9, 109.6 0.65
76
ITT Population
Population asTreated
D Mixed Model Range P-value
3-months 61.0 -2.9, 124.8 0.06
6-months 46.2 -28.0, 120.4 0.22
12-months 36.6 -56.1, 129.2 0.43
![Page 77: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/77.jpg)
Primary Endpoint asTreated
MEAN MEDIAN
![Page 78: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/78.jpg)
MEAN MEDIAN
![Page 79: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/79.jpg)
As Treated
0.63 P=0.05
79
6 months Relative Risk
ITT
0.58 P=0.02
![Page 80: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/80.jpg)
Results: 2-Year MACE
80
Standard ofCare
(n=28)
Act iveCont rol(n=28)
CD34+ Cel lTxt (n=50)
StartedMobi l izat ion
but NotInjected
(n=6)Pat ients wi thMACE
19 (67.9%) 12 (42.9%) 23 (46.0%) 2 (33.3%)
Death2 (7.1%) 3 (10.7%) 2 (4.0%) 0
MI2 (7.1%) 3 (10.7%) 5 (10.0%) 2 (33.3%)
Perforat ion0 0 2 (4.0%) 1* (16.7%)
Stroke- - - -
CVhospi tal izat ion
18 (64.3%) 9 (32.1%) 21(42.0%) 2 (33.3%)
Vent r iculararrhythmias
1(3.6%) 2 (7.1%) 1(2.0%) -
MACE <2 weeks0 0 3 (6.0%) 2 (33.3%)
MACE dur ingfol low-up
19 (67.9%) 12 (42.9%) 21(42.0%) 2 (33.3%)
![Page 81: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/81.jpg)
![Page 82: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/82.jpg)
ConclusionsTrial stopped prematurely for strategic/ financialreasons
Positive improvements in angina, exercise timeandmortality consistent with Phase 2 data
Standard of carearm did very poorly
Utility of CD34+ cells for refractory angina remainsvery promising but incompletely defined
82
![Page 83: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/83.jpg)
SSO2 Therapy Devices
83
IVTubing
OxygenChamber
Blood MixingChamber
Pressure Transducer
Draw Tubing
Piston Chamber
Fluid Manifold
IV Tubing
PistonChamber
OxygenChamber Blood
MixingChamber
FluidManifold
PressureTransducer
Draw Tubing
Return Tubing
DownStream System
DownStream Cartridge
SSO2 DeliveryCatheter
![Page 84: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/84.jpg)
Clinical Outcomes
84
Schomig A et al. N Engl JMed 2000;343:385-91
Reducing Infarct Size by 5% Improves Clinical Outcomes
![Page 85: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/85.jpg)
Size Results
85
Med
ian
Infa
rct
Siz
e(%
LV)
0
5
10
15
20
25
30
26.5%
20.0%
25.0%
18.5%
Control SSO2 Therapy
72 209 124 258 18
9.6%
![Page 86: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/86.jpg)
INFARCTSIZEANDSURVIVAL
![Page 87: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/87.jpg)
NEW TRIALSCARDIOAMP
CHF
CHART 3
CHF
RECARDIO
CHF
COMBINATION THERAPY
GCSF
FACTOR X
![Page 88: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/88.jpg)
CONCLUSIONSGENE THERAPY IS DEADSTEM CELLS ARE ALIVE AND WELLPHASE I-II TRIALS POSITIVEPHASE III ONGOINGRECRUITMENT VERY DIFFICULTSTILL QUESTIONS REMAIN
BEST CELL?DOSE?DELIVERY?STUDY DESIGN?CHF VS ANGINA?
FDAAPPROVAL 7-10 YEARS?
![Page 89: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/89.jpg)
KEEPITSIMPLE!
![Page 90: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/90.jpg)
![Page 91: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/91.jpg)
THANKYOUDR JIM MASON
DR BILL MILLER
HEMATOLOGY STAFF
BM TRANSPLANT SERVICE
DR ROSSRUDOLPH
![Page 92: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/92.jpg)
THANKYOUGEORGE AND NORMA PLEWES
JIM NEWMAN
SID AND JENNY CRAIG
DR ERIC TOPOL
DR LARRY KLINE
![Page 93: 0400 CELL THERAPY 2016 - Promedica International · 2019. 5. 24. · D/CIN 24 HOURS TERMINATED FOR3STROKES. AASTROM TRIAL 15O PATIENTSPHASEII ... p=0.495 p=0.433. Baseline(B) and](https://reader033.fdocuments.us/reader033/viewer/2022060718/607e9dcaeebce029f97dc0f2/html5/thumbnails/93.jpg)
ADRCs: Mechanism of Action
93
Note: Thegrowth factorsand cell types listed here are by way of exampleand are not an exhaustive list of thecellsand factors involved